{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T04:10:01Z","timestamp":1733544601965,"version":"3.30.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,12,1]]},"DOI":"10.2169\/internalmedicine.3322-23","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T22:14:05Z","timestamp":1712614445000},"page":"3233-3236","source":"Crossref","is-referenced-by-count":0,"title":["Successful Pregnancy and Delivery after Frozen-thawed Embryo Transfer Following the Third Discontinuation of Tyrosine Kinase Inhibitor in a Woman with Chronic Myeloid Leukemia"],"prefix":"10.2169","volume":"63","author":[{"given":"Kosuke","family":"Takayama","sequence":"first","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Katsuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Murase","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 19: 497-499, 2005.","DOI":"10.1038\/sj.leu.2403686"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sasaki K, Strom SS, O&apos;Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2: e186-e193, 2015.","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 29: 1336-1343, 2015.","DOI":"10.1038\/leu.2015.73"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Furukawa Y, Takahashi T, Suganuma R, et al. Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review. Mediterr J Hematol Infect Dis 12: e2020005, 2020.","DOI":"10.4084\/mjhid.2020.005"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Legros L, Nicolini FE, Etienne G, et al.; the French Intergroup for Chronic Myeloid Leukemias. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer 123: 4403-4410, 2017.","DOI":"10.1002\/cncr.30885"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6: e2014028, 2014.","DOI":"10.4084\/mjhid.2014.028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Salem W, Ho JR, Woo I, et al. Long-term imatinib diminishes ovarian reserve and impacts embryo quality. J Assist Reprod Genet 37: 1459-1466, 2020.","DOI":"10.1007\/s10815-020-01778-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Balsat M, Etienne M, Elhamri M, Hayette S, Salles G, Thomas X. Successful pregnancies in patients with BCR-ABL positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era. Eur J Haematol 101: 774-780, 2018.","DOI":"10.1111\/ejh.13167"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-\u03b1 in 1<sup>st<\/sup> trimester: report of 3 cases and review of the literature. Am J Hematol 69: 115-118, 2002.","DOI":"10.1002\/ajh.9876"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 33: 265-268, 2012.","DOI":"10.1016\/j.reprotox.2011.11.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. O&apos;Brien SG, Guilhot F, Larson RA, et al.; the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003.","DOI":"10.1056\/NEJMoa022457"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol 90: 1111-1115, 2015.","DOI":"10.1002\/ajh.24186"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27: 241-243, 2007.","DOI":"10.1038\/sj.jp.7211665"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs 23: 754-757, 2012.","DOI":"10.1097\/CAD.0b013e328352a8fe"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chelysheva E, Turkina A, Polushkina E, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma 59: 733-738, 2018.","DOI":"10.1080\/10428194.2017.1347929"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol 11: 2040620720966120, 2020.","DOI":"10.1177\/2040620720966120"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yukiko K, Seung CJ, Akira K, et al. Assisted technology in Japan: a summary report for 2020 by the ethics Committee of the Japan Society of obstetrics and gynecology. Reprod Med Biol 22: e12494, 2023.","DOI":"10.1002\/rmb2.12494"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Weng S, Huang Y, Huang Y, Li Y, Chien L. Assisted reproductive technology and risk of childhood cancers. JAMA Netw Open 5: e2230157, 2022.","DOI":"10.1001\/jamanetworkopen.2022.30157"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/23\/63_3322-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T03:30:04Z","timestamp":1733542204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/23\/63_3322-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":18,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3322-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"article-number":"3322-23"}}